Last edition
News about
AstraZeneca Acquires Full Global Rights to AbelZeta's CAR-T Therapy C-CAR031 in USD 630 Million Deal
AstraZeneca has acquired AbelZeta Pharma’s China rights to CAR-T therapy C-CAR031 for up to USD 630 million, securing full global development and commercialisation rights for the liver cancer treatment.
Syngene Renews Long-Term Research Alliance with Bristol Myers Squibb Until 2035
Syngene International has extended its long-term research collaboration with Bristol Myers Squibb until 2035, expanding the partnership to cover integrated services across the drug development lifecycle, from discovery and translational sciences to manufacturing, clinical trials and commercialisation support.
Brenig Therapeutics Initiates First-in-Human Study of BT-409, Advances BT-267 Parkinson's Programme
Brenig Therapeutics has launched a first-in-human Phase I study of BT-409, a brain-selective NLRP3 inhibitor, while advancing BT-267 toward Phase 1b and Phase II studies in Parkinson’s disease.
Concept Life Sciences has appointed Dr Adam Davenport as Chief Scientific Officer (CSO), who brings over 25 years of expertise in life sciences and partnership management to advance the company’s leadership in integrated drug discovery.
EU Validates ENHERTU Plus Pertuzumab for First-Line HER2-Positive Metastatic Breast Cancer
The European Union (EU) has validated the first-line use of ENHERTU in combination with pertuzumab for patients with HER2-positive metastatic breast cancer, following results from the DESTINY-Breast09 phase-III trial, which demonstrated a significant improvement in Progression-Free Survival (PFS) compared to current standard treatments.
Brazil and Nigeria Emerge as High-Growth Markets for Indian Pharma Exports
During the April–November period of the current financial year, pharmaceutical exports to Nigeria recorded a sharp increase, making it one of the fastest-growing destinations for Indian drug makers.
Elanco Expands TruCan Vaccine Portfolio with USDA-Approved Oral Bordetella Shot
Elanco Animal Health Incorporated has received approval from the US Department of Agriculture (USDA) for TruCan Ultra B (Oral), a next-generation oral vaccine designed to protect dogs against Bordetella bronchiseptica, a key cause of canine infectious respiratory disease complex (CIRDC), commonly known as kennel cough.
AbbVie reported positive Phase III results showing epcoritamab improved progression-free survival versus standard chemoimmunotherapy in relapsed/refractory diffuse large B-cell lymphoma, reinforcing its potential as a CD3xCD20 bispecific therapy.
European Commission Approves Sobi's Aspaveli for Rare Kidney Diseases C3G and IC-MPGN
The European Commission has approved Sobi’s Aspaveli for adolescents and adults with rare kidney diseases C3G and IC-MPGN, marking the first approved therapy for these conditions.
Novartis' Ianalumab Receives FDA Breakthrough Therapy Designation for Sjogren's Disease
The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease, accelerating its review as a potential first targeted treatment, with global filings planned from 2026.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy